{"id":847706,"date":"2025-05-06T16:44:27","date_gmt":"2025-05-06T20:44:27","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cellectis-to-report-first-quarter-financial-results-on-may-12-2025\/"},"modified":"2025-05-06T16:44:27","modified_gmt":"2025-05-06T20:44:27","slug":"cellectis-to-report-first-quarter-financial-results-on-may-12-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cellectis-to-report-first-quarter-financial-results-on-may-12-2025\/","title":{"rendered":"Cellectis to Report First Quarter Financial Results on May 12, 2025"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">NEW YORK, May  06, 2025  (GLOBE NEWSWIRE) &#8212; Cellectis (the \u201cCompany\u201d) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the first quarter 2025 ending March 31, 2025 on Monday, May 12, 2025 after the close of the US market.<\/p>\n<p align=\"justify\">The press release will be available in the Investors section of Cellectis\u2019 website: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=94fQJEZolwzyyTe2mMBQ7R1vrN1HFQsmN8S2XFPnkQ2Z9m-6JDZd2ET6lTgO-uwdQn038WTXWKmMeJR18wEKba0_bcpZdQZ2DK8mLg_dsv4LgviVTApR6T3QBi8q07fATS66MA6yPZm7ZPBbo8jEeh2PNYAhupWPV1EmthxuS0-LwnEkujWAet8vM08EjNjH\" rel=\"nofollow\" target=\"_blank\">https:\/\/www.cellectis.com\/en\/investors\/press-releases\/<\/a><\/p>\n<p align=\"justify\">Cellectis will not host a conference call to discuss these results. Our investors relations team remains available for questions at <u>investors@cellectis.com<\/u>\u00a0\u00a0\u00a0\u00a0\u00a0<\/p>\n<p>\n        <strong>About Cellectis<\/strong>\u00a0<\/p>\n<p align=\"justify\">Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company utilizes an allogeneic approach for CAR T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to develop gene therapies in other therapeutic indications. With its in-house manufacturing capabilities, Cellectis is one of the few end-to-end gene editing companies that controls the cell and gene therapy value chain from start to finish.<\/p>\n<p align=\"justify\">Cellectis\u2019 headquarters are in Paris, France, with locations in New York and Raleigh, NC. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS).\u00a0To find out more, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=NMUpedAXg4_WFJJ1PoUnX1VX_T7C4l-DjBzyDpRzZAbcWK9GZrKDkR7pKwOtC-BeWxEl4N1nmCSUsVHaN6URnzr6SPUIXXS8TMsWIaDbmJk=\" rel=\"nofollow\" target=\"_blank\">www.cellectis.com<\/a> and follow Cellectis on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=UPK_4CLtMwoWUQhw4ttUlKA3MB2jZWQaC4g2IuApiv8kTkQuuk9QiW7JwKFkWG2MVPPdg42ZOcRVKojlx6kYTe0NyDx7c3U38neTrxWo4AL9gR0V40TrtGGc3Uz1MkBT\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=qkA96szDBln49l92yD5qHWZVb8DPZ3mRDHloeNuQeqdRDXj_8CZJPXL4P4JRvykZN9Sn5lzmwwK_TQPoEOkcfw==\" rel=\"nofollow\" target=\"_blank\">X<\/a>.<\/p>\n<p>\n        <strong>For further information on Cellectis, please contact:<\/strong>\u00a0\u00a0\u00a0\u00a0<\/p>\n<p align=\"justify\">\n        <strong>Media contacts:<\/strong>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<br \/>Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=XDu_fcyiHBMcEW86v07HJ6i8QRoRVJFGs4mdrAFXqfAVRulp8kI2mMXvFp2ay1ghIQqhVBEhY-LzFQrd62uv6xmoSliGmf9Cw9q4DtaXi7A=\" rel=\"nofollow\" target=\"_blank\">media@cellectis.com<\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ycvjxa4xujc6yXF02T0J2mKwuF5btaYJOhcK13T2yWTjWUoTJnD47inhuoKneKajsc4JyjsHZjqrUYeBqx7_vQ==\" rel=\"nofollow\" target=\"_blank\"><br \/><\/a>Patricia Sosa Navarro, Chief of Staff to the CEO,\u00a0+33 (0)7 76 77 46 93<\/p>\n<p align=\"justify\">\n        <strong>Investor Relations contact:<\/strong>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<br \/>Arthur Stril, Chief Financial Officer &amp; Chief Business Officer, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=BTDuJbgV0x7XLNs1vxW7R0hl-Y8D-7-CcYb0FUwzLV10kNGWlqM9t14XzwVh9AzV39D9b7gw8m0M6Rn9_chO14_1RB6IIGK6oywqLlS1N64=\" rel=\"nofollow\" target=\"_blank\"><u>investors@cellectis.com<\/u><\/a>\u00a0<\/p>\n<p align=\"justify\">\u00a0<\/p>\n<p id=\"gnw_attachments_section-header\">\n        <strong>Attachment<\/strong>\n      <\/p>\n<ul id=\"gnw_attachments_section-items\">\n<li>\n          <a href=\"https:\/\/ml.globenewswire.com\/Resource\/Download\/fddf7d60-0bb7-4b95-af3f-efc6656df643\" rel=\"nofollow\" target=\"_blank\">20250506_FY 2024 earnings call announcement_ENGLISH<\/a>\n        <\/li>\n<\/ul>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0NTQzNSM2OTIzODkzIzIwNDk4Nzc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MmEyZGMxMjktNWFlNC00Yjc1LTlmZDMtOTczYTM5YjBiYzliLTEwNjE0NDgtMjAyNS0wNS0wNi1lbg==\/tiny\/Cellectis-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) &#8212; Cellectis (the \u201cCompany\u201d) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the first quarter 2025 ending March 31, 2025 on Monday, May 12, 2025 after the close of the US market. The press release will be available in the Investors section of Cellectis\u2019 website: https:\/\/www.cellectis.com\/en\/investors\/press-releases\/ Cellectis will not host a conference call to discuss these results. Our investors relations team remains available for questions at investors@cellectis.com\u00a0\u00a0\u00a0\u00a0\u00a0 About Cellectis\u00a0 Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company utilizes an &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cellectis-to-report-first-quarter-financial-results-on-may-12-2025\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Cellectis to Report First Quarter Financial Results on May 12, 2025&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-847706","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cellectis to Report First Quarter Financial Results on May 12, 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cellectis-to-report-first-quarter-financial-results-on-may-12-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cellectis to Report First Quarter Financial Results on May 12, 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) &#8212; Cellectis (the \u201cCompany\u201d) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the first quarter 2025 ending March 31, 2025 on Monday, May 12, 2025 after the close of the US market. The press release will be available in the Investors section of Cellectis\u2019 website: https:\/\/www.cellectis.com\/en\/investors\/press-releases\/ Cellectis will not host a conference call to discuss these results. Our investors relations team remains available for questions at investors@cellectis.com\u00a0\u00a0\u00a0\u00a0\u00a0 About Cellectis\u00a0 Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company utilizes an &hellip; Continue reading &quot;Cellectis to Report First Quarter Financial Results on May 12, 2025&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cellectis-to-report-first-quarter-financial-results-on-may-12-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-06T20:44:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0NTQzNSM2OTIzODkzIzIwNDk4Nzc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cellectis-to-report-first-quarter-financial-results-on-may-12-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cellectis-to-report-first-quarter-financial-results-on-may-12-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cellectis to Report First Quarter Financial Results on May 12, 2025\",\"datePublished\":\"2025-05-06T20:44:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cellectis-to-report-first-quarter-financial-results-on-may-12-2025\\\/\"},\"wordCount\":282,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cellectis-to-report-first-quarter-financial-results-on-may-12-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ0NTQzNSM2OTIzODkzIzIwNDk4Nzc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cellectis-to-report-first-quarter-financial-results-on-may-12-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cellectis-to-report-first-quarter-financial-results-on-may-12-2025\\\/\",\"name\":\"Cellectis to Report First Quarter Financial Results on May 12, 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cellectis-to-report-first-quarter-financial-results-on-may-12-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cellectis-to-report-first-quarter-financial-results-on-may-12-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ0NTQzNSM2OTIzODkzIzIwNDk4Nzc=\",\"datePublished\":\"2025-05-06T20:44:27+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cellectis-to-report-first-quarter-financial-results-on-may-12-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cellectis-to-report-first-quarter-financial-results-on-may-12-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cellectis-to-report-first-quarter-financial-results-on-may-12-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ0NTQzNSM2OTIzODkzIzIwNDk4Nzc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ0NTQzNSM2OTIzODkzIzIwNDk4Nzc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cellectis-to-report-first-quarter-financial-results-on-may-12-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cellectis to Report First Quarter Financial Results on May 12, 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cellectis to Report First Quarter Financial Results on May 12, 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cellectis-to-report-first-quarter-financial-results-on-may-12-2025\/","og_locale":"en_US","og_type":"article","og_title":"Cellectis to Report First Quarter Financial Results on May 12, 2025 - Market Newsdesk","og_description":"NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) &#8212; Cellectis (the \u201cCompany\u201d) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the first quarter 2025 ending March 31, 2025 on Monday, May 12, 2025 after the close of the US market. The press release will be available in the Investors section of Cellectis\u2019 website: https:\/\/www.cellectis.com\/en\/investors\/press-releases\/ Cellectis will not host a conference call to discuss these results. Our investors relations team remains available for questions at investors@cellectis.com\u00a0\u00a0\u00a0\u00a0\u00a0 About Cellectis\u00a0 Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company utilizes an &hellip; Continue reading \"Cellectis to Report First Quarter Financial Results on May 12, 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cellectis-to-report-first-quarter-financial-results-on-may-12-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-05-06T20:44:27+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0NTQzNSM2OTIzODkzIzIwNDk4Nzc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cellectis-to-report-first-quarter-financial-results-on-may-12-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cellectis-to-report-first-quarter-financial-results-on-may-12-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cellectis to Report First Quarter Financial Results on May 12, 2025","datePublished":"2025-05-06T20:44:27+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cellectis-to-report-first-quarter-financial-results-on-may-12-2025\/"},"wordCount":282,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cellectis-to-report-first-quarter-financial-results-on-may-12-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0NTQzNSM2OTIzODkzIzIwNDk4Nzc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cellectis-to-report-first-quarter-financial-results-on-may-12-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cellectis-to-report-first-quarter-financial-results-on-may-12-2025\/","name":"Cellectis to Report First Quarter Financial Results on May 12, 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cellectis-to-report-first-quarter-financial-results-on-may-12-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cellectis-to-report-first-quarter-financial-results-on-may-12-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0NTQzNSM2OTIzODkzIzIwNDk4Nzc=","datePublished":"2025-05-06T20:44:27+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cellectis-to-report-first-quarter-financial-results-on-may-12-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cellectis-to-report-first-quarter-financial-results-on-may-12-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cellectis-to-report-first-quarter-financial-results-on-may-12-2025\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0NTQzNSM2OTIzODkzIzIwNDk4Nzc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0NTQzNSM2OTIzODkzIzIwNDk4Nzc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cellectis-to-report-first-quarter-financial-results-on-may-12-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cellectis to Report First Quarter Financial Results on May 12, 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/847706","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=847706"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/847706\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=847706"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=847706"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=847706"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}